2016-2018年中国人民解放军总医院口服调节血脂药使用情况分析

Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018

目的:了解2016—2018年中国人民解放军总医院(以下简称“我院”)口服调节血脂药使用情况及变化趋势,为临床合理用药和管理提供参考依据。方法:通过医院信息系统,提取2016—2018年我院口服调节血脂药相关使用数据,对各类药品的销售金额、用药频度(defined daily dose system,DDDs)、限定日费用(defined daily cost,DDC)和药品销售金额排序(B)/DDDs排序(A)的比值等进行回顾性分析。结果:2016—2018年我院口服调节血脂药中,他汀类药物的销售金额排序始终居首位,阿托伐他汀、瑞舒伐他汀和匹伐他汀的销售金额排序、DDDs排序连续3年居前3位;普罗布考和辛伐他汀的销售金额、DDDs呈逐年降低趋势;普伐他汀和阿昔莫司的销售金额、DDDs相对比较平稳;依折麦布的销售金额、DDDs在2018年呈明显升高趋势,其排序均由第8位升至第4位;非诺贝特、氟伐他汀和多廿烷醇的销售金额排序、DDDs排序一直居后3位。3年来,我院口服调节血脂药的DDC呈逐年降低趋势;多廿烷醇的DDC排序均居首位。普罗布考的B/A<1,阿昔莫司的B/A>1,其他调节血脂药的B/A为1。结论:我院口服调节血脂药的使用情况基本合理,符合当前指南推荐的用药原则。

OBJECTIVE:To investigate the application and its trend of oral lipid-regulating drugs in China PLA General Hospital(hereinafter referred to as“our hospital”)during 2016-2018,so as to provide references for clinical rational drug application and management.METHODS:Through Hospital Information System,data related to oral lipid-regulating drugs in our hospital during 2016-2018 were extracted and retrospectively analyzed in terms of consumption sum,defined daily dose system(DDDs),defined daily cost(DDC)and ratio of sequence of consumption sum(B)/sequence of DDDs(A).RESULTS:Among the oral lipid-regulating drugs in our hospital during 2016-2018,the consumption sum of statins had always ranked the first,the top 3 drugs ranked by consumption sum and DDDs in the continuous 3 years were respectively atorvastatin,rosuvastatin and pivastatin;the consumption sum and DDDs of probucol and simvastatin decreased year by year;the consumption sum and DDDs of pravastatin and acipimox were relatively stable;the consumption sum and DDDs of ezetimibe showed significantly increasing trend in 2018,and its ranking rose from 8th to 4th;the consumption sum and DDDs of fenofibrate,fluvastatin and policosanol had always been the bottom 3.In the past three years,the DDC of oral lipid-regulating drugs in our hospital decreased year by year;the DDC of policosanol ranks first.The B/A of Probucol was<1,acipimox was>1,and the B/A of other lipid-regulating drugs were 1.CONCLUSIONS:The application of oral lipid-regulating drugs in our hospital is basically rational,which meets the medication principle of current guideline recommendation.